Side-by-side IPO readiness, funding history, and valuation comparison. Data sourced by TechStackIPO.
Scores, valuations, and signals for Faire, Generate Biomedicines, and 370+ companies. 5-min read every Tuesday.
Faire is the wholesale marketplace connecting 700K+ independent retailers with 100K+ emerging brands — the B2B commerce platform for the indie retail economy. Valued at $12.4B with $1.7B raised, Faire processes billions in annual GMV and is the dominant wholesale marketplace globally. IPO candidate as B2B commerce digitisation continues to disrupt traditional wholesale distribution — a $50B+ global market.
| Industry | E-commerce |
| Stage | Series H |
| IPO Status | Private |
| Valuation | $12.4B |
| Total Funding | $1.7B |
| Headquarters | San Francisco, CA |
Generate Biomedicines uses AI diffusion models and large-scale protein language models to generate novel therapeutic proteins and entire molecules from scratch — designing drugs that have never existed before in weeks instead of years. Valued at $1.2B with $400M raised from Andreessen Horowitz, Generate Biomedicines has multiple preclinical programs in oncology and immunology. Major AI biotech IPO candidate as AI-driven protein generation transforms pharmaceutical R&D from a trial-and-error process into a computational engineering discipline.
| Industry | Biotechnology |
| Stage | Series A |
| IPO Status | Private |
| Valuation | $1.2B |
| Total Funding | $150M |
| Headquarters | Cambridge, MA |
Complete funding history, cap table, S-1 analysis, and investor breakdown for any company. Instant PDF download.
Or buy any single company report for $19
Faire is valued at $12.4B. Generate Biomedicines is valued at $1.2B. Both figures are based on the most recent funding rounds tracked by TechStackIPO.
Faire filed an S-1 in April 2026 and is actively in the IPO pipeline. Generate Biomedicines is currently private. Track both companies on TechStackIPO for S-1 filings, roadshow announcements, and IPO date updates.
Faire has raised $1.7B. Generate Biomedicines has raised $150M.
Faire operates in E-commerce, while Generate Biomedicines operates in Biotechnology.
Faire is a E-commerce company valued at $12.4B with $1.7B raised. Generate Biomedicines is a Biotechnology company valued at $1.2B with $150M raised. See TechStackIPO's full side-by-side comparison for IPO readiness scores, funding timelines, and investor access options.
Accredited investors can access pre-IPO shares in Faire and Generate Biomedicines through secondary market platforms, pre-IPO funds, and broker-dealer platforms that facilitate private company transactions. TechStackIPO's marketplace section tracks available access options for both companies. Pre-IPO investments carry higher risk and limited liquidity.